Immune Cell Therapy PatientCustomized Cancer Therapy

1
Above all else, guard your heart, it is the
wellspring of life Proverbs 423
2
Forward Looking Statement
3
Significance of Heart Failure
3

• 1 Patient Diagnosis Over Age 65
• 1 Cause of Death Over Age 65
• 1 Hospital Expense at 15 Billion
• Over 1 Million Hospitalizations Annually

80 Over Age 65 Will Die of Heart Failure
4
Current Treatments

• Diuretics to Remove Excess Fluids
• ACE Inhibitors for Hypertension
• Beta Blockers to Slow Heart Rate
• Vasodilators to Reduce Heart Pumping Effort

Multiple Drugs Required for Treatment
5
Goals of Our Therapy

• Reduce Hospital Readmission Rate by Half
• Reduce Annual Hospital Costs by 6 Billion
• Eliminate 400,000 Readmissions
• Save 16,000 per Hospital Visit
• Provide Longer and Healthier Quality of Life

6
Calcitonin Gene Related Peptide (Human CGRP)

• Significant Body of Research
• Clinical Profile
• Improves Cardiac Function
• Maintains Kidney Blood Flow
• Cardioprotective
• Reduces Cardiac muscle Inflammation
• Established Human Safety Profile

Calcitonin Gene Related Peptide
7
Human CGRP Agonist Analogs

• IP protected
• Synthesized, characterized, tested
• In-vitro, In-vivo bio-activity confirmation
  human aCGRP
• Clinical Profile Expectations
• to CGRP
• Differentiation of effects based on structure
• Tailorable to indication

CGRP Agonists
Could Become a Platform Technology
8
Clinical ExpectationsOptimized Dose of 0.008
µg/kg/min
Source Anand 1991 Shekhar 1991
9
Product 1 In-Hospital

• Provides Combined Benefits of Several Drugs
• IV Administration
• Stabilization of Symptoms
• Reduce Hospitalization Time

10
Product 2 Post-Hospital
10

• Controlled Release Drug
• Easy to Administer
• Requires Only Periodic Administration
• Continuous Treatment

11
Product 2 Post-Hospital
11

• First 7 days after discharge or out-patient
• Greatest unmet need in heart failure treatment
• Cardiologists need treatment options
• CGRP analog can meet the need
• CGRP recognized as having the right therapeutic
  qualities to meet this need
• Stabilize heart failure symptoms and reduce
  re-hospitalizations

Major Market Differentiation
12
Intellectual Property

• 13 US and Foreign Patent Applications
• Heart Failure
• Acute MI
• Renal Insufficiency
• Controlled Release
• CGRP and CGRP Agonist Analogs
• 5 Patents In Process
• New Drug Applications

Heart and Kidney Focused
13
VasoGenix Leadership Team

• Board of Directors
• Lee Southard, PhD Chairman
• Richard Dunn, PhD Former Sr. VP Drug Delivery
  Research, QLT/Atrix Laboratories
• Donald Braun, PhD Vice President, Clinical
  Research, Cancer Treatment Centers of America
• Thomas Noffsinger, PhD Former Assistant
  Vice-Chancellor, KUMC Research Institute
• Scientific Advisory Board
• Clinical Research Steering Committee

Experience from Drug Discovery to FDA Approval
14
Management

• Dr. G. Lee Southard
• President Chief Executive Officer
• Atrix Laboratories, Inc.
• Founder, President, CEO CSO 19871998
• Increased Share Price from .50 to 29
• Company Sold to QLT Inc. for 855 million
• Vipont Pharmaceuticals, Inc.
• Co-founder, VP RD 1981-1986
• Increased Share Price from .50 to 15
• Company Sold to Colgate-Palmolive for 94 million
• Big Pharma Executive Experience
• Eli Lilly
• Johnson Johnson

10 FDA Approved Drug and Device Products
15
Management

• Jeff Southard
• Co-Founder Vice President Drug Development
• 6 New Drugs to Market
• 3 New Medical Devices
• 5 Patents Issued, 3 Patents Pending
• 13 Publications and Presentations
• Big Pharma and CRO Experience

20 Years Drug Discovery and Development
16
Using SpecialistsPartners in Development

• Pre-Clinical Testing
• Xenometrics
• Acceleration, LLC
• GEL Analytics, Inc.
• Fleishman-Hillard
• Kidney Institute of Kansas University Medical
  Center (KUMC)
• Mid America Cardiology Associates at KUMC

17
Pre-Clinical Research
CGRP Analog Profiling
18
Using SpecialistsPartners in Development

• Research Collaborations
• Tulane University School of Medicine
• CGRP Protects Heart Cells from Death During Heart
  Attack Heart Failure Conditions
• (American Heart Association 2005)
• Cleveland Clinic Lerner Research Institute
• CGRP Receptors in Heart Failure Patients Are
  Upregulated 38
• (American Heart Association 2007)

19
Using SpecialistsPartners in Development

• Manufacturing
• New England Peptides, LLC
• PolyPeptide Laboratories, Inc.
• Regulatory Consulting
• Beckloff Associates, Inc.
• LIPICKY, LLC
• Clinical Testing
• Cleveland Clinic
• Averion

20
Clinical Trials
Proof of Concept and Phase I/II
21
Development Timeline
Exit Opportunity 1
Focused on Exit Opportunity
22
Financing to Date
22

• Raised 4.5 Million
• Synthesis and Characterization of New Analogs of
  CGRP In-vitro and in-vivo
• Established clear market differentiation
• Initial Development of Controlled Release
• Pre-IND Meeting with FDA
• Strengthened Intellectual Property
• Established Development Plan

23
Summary
23

• Exciting New Series of Compounds
• IP Strong
• Clear HF market application
• Revenue Projections Excellent
• Developmental Partners The Best
• Two Years to Clinic
• Four years to Exit

24
Revenue Projection
25
VasoGenix Pharmaceuticals 8527 Bluejacket
Street Lenexa, Kansas 66214 Dr. G. Lee
Southard Jeff Southard southardl_at_earthlink.net
jsouthard_at_vasogenix.us